C4 Therapeutics Shares Phase 1 Cemsidomide Data at IMS

Author: Dylan Bailey Updated: 09-03-2025 07:16 AM

C4 Therapeutics Presents Compelling Data on Cemsidomide

C4 Therapeutics, Inc. (C4T), a progressive biopharmaceutical company focused on targeted protein degradation, has revealed exciting insights from its Phase 1 clinical trial of cemsidomide for treating multiple myeloma (MM). This data will be shared in an oral presentation set for the International Myeloma Society (IMS) Annual Meeting.

Upcoming IMS Annual Meeting Presentation Details

The presentation, titled "Updated Results of a Phase 1 First-in-Human Study of Cemsidomide (CFT7455) with Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma," highlights significant progress in cemsidomide's development. It is scheduled for September 20, 2025, at 11:10 AM ET, during the session focused on future therapeutic targets.

Location and Key Presenter

The presentation will occur at the Metro Toronto Convention Centre, with Dr. Binod Dhakal from the Medical College of Wisconsin leading the discussion. His expertise in hematology will add depth to the information provided, aiming to capture the attention of attendees eager to learn about innovative treatments in MM.

Phase 1 Trial Insights

C4T has successfully completed patient enrollment and dose escalation for the clinical trial, which continues to exhibit a favorable safety profile and encouraging response rates. Data presented at the IMS will encompass all evaluable patients across the various dose levels of cemsidomide combined with dexamethasone.

Webcast Highlights Post-Presentation

Following the IMS presentation, C4T will host a webcast on the same day at 3 PM ET. This online event aims to delve deeper into the data and discuss the company's future clinical development strategies. Interested participants can find further details on the company's website.

About C4 Therapeutics

C4 Therapeutics stands at the forefront of biopharmaceutical innovation, dedicated to enhancing patient lives through targeted therapies. Leveraging its proprietary TORPEDO platform, C4T designs advanced small-molecule medicines that tackle challenging diseases. Their approach harnesses the body’s natural systems to degrade harmful proteins, offering potential solutions to issues like drug resistance.

Exploring Cemsidomide

Cemsidomide is an investigational drug noted for its potential effectiveness in targeting IKZF1 and IKZF3 transcription factors, which play a significant role in the progression of MM and non-Hodgkin’s lymphomas. Clinical data suggests that it is well tolerated and shows promise in anti-myeloma activity.

Contact Information

For further inquiries, C4T encourages interested parties to reach out to:

Investors: Courtney Solberg, Associate Director, Investor Relations (CSolberg@c4therapeutics.com)

Media: Loraine Spreen, Senior Director, Corporate Communications & Patient Advocacy (LSpreen@c4therapeutics.com)

Frequently Asked Questions

What is C4 Therapeutics known for?

C4 Therapeutics specializes in advanced biopharmaceuticals, focusing on targeted protein degradation and innovative treatment solutions.

When will the IMS Annual Meeting presentation take place?

The presentation is scheduled for September 20, 2025, at 11:10 AM ET.

Who will present the data at the IMS Annual Meeting?

Dr. Binod Dhakal will be the key presenter, sharing insights from the trial data.

What is the main focus of the Phase 1 trial?

The trial focuses on the effectiveness and safety of cemsidomide in patients with relapsed/refractory multiple myeloma.

How can I access the webcast after the presentation?

The webcast will be available on the C4 Therapeutics website, allowing viewers to catch up on detailed insights offered during the event.

About The Author

My name is Dylan Bailey, and I am 28 years old. I am an author and an expert on the stock market who specializes in publicly traded companies. Early fascination with the stock market inspired me to seek a finance degree and then delve deeply into the world of stocks. I have developed over the years my abilities to spot investment prospects, assess business performance, and analyze market trends.

My books and articles try to help regular investors understand the nuances of the stock market. Anyone can, in my opinion, make wise investment choices and succeed financially if they have the correct information and resources. In my writing, I combine in-depth research with practical insights and advice that can be put into action. This is done with the intention of assisting readers in navigating the constantly shifting landscape of publicly traded companies.

In addition to writing, I also host webinars and workshops, where I give presentations and share my knowledge with a wider audience. I also write for top financial journals and show up as a guest analyst on financial news shows. I like to travel, spend time with my family, and keep active by playing different sports when I'm not buried in market research.

My goal is to enable people to choose wisely and consciously in their investments, so taking charge of their financial futures. By my work, I hope to create a community of informed and self-assured investors prepared to take advantage of the chances presented by the stock market.

Contact Dylan Bailey privately here. Or send an email with ATTN: Dylan Bailey as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.